Genentech's Lymphoma Drug Combo Wows in Mid-Stage Trial
These data led to FDA Breakthrough Therapy and EMA PRIME (PRIority MEdicines) designations. Source: BioSpace
These data led to FDA Breakthrough Therapy and EMA PRIME (PRIority MEdicines) designations. Source: BioSpace
Layoffs are expected to begin in February, according to reports. Source: BioSpace
The expansion will nearly double its employment. Source: BioSpace
One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients. Source:…
Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time. Source: BioSpace
Biotech companies have a number of pivotal challenges in going from a promising compound to commercially viable products. Source: BioSpace
Boston Business Journal pulled together a list of the 25 biggest gainers in the state for 2017, and five of them are biopharma companies. Source: BioSpace
The company indicates it plans to continue to manage and operate under the bankruptcy filing while it works with Cowen and Company to develop a plan forward. Source: BioSpace
The trial met its primary endpoint of progression-free survival but did not improve overall survival, a secondary endpoint. Source: BioSpace
With the raise, the company's market valuation is currently $1.7B. Source: BioSpace